• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For Eli Lilly (LLY) Could Change Following Retatrutide Milestone And Governance Shift - Learn Why

    Simply Wall St·03/26/2026 19:09:07
    Listen to the news
    • Eli Lilly recently reported strong Phase 3 results for its investigational triple-agonist retatrutide in type 2 diabetes and positive pediatric data for EBGLYSS in atopic dermatitis, while Fauna Bio announced the first target from its obesity discovery collaboration with Lilly and the company moved to remove supermajority voting from its bylaws ahead of the May 2026 shareholder meeting.
    • Together, these updates highlight Lilly’s push to deepen its cardiometabolic and immunology franchise, expand next-generation obesity research through AI-driven partnerships, and incrementally strengthen shareholder governance.
    • Next, we’ll examine how retatrutide’s late-stage success and expanding obesity ecosystem could reshape Eli Lilly’s investment narrative for investors.

    Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

    Eli Lilly Investment Narrative Recap

    To own Eli Lilly, you need to believe in the durability of its incretin-led obesity and diabetes franchise, and in its ability to broaden beyond a few blockbuster drugs. The latest retatrutide and EBGLYSS data support that diversification, while the Fauna Bio update and proposed end to supermajority voting do not materially change the key near term catalyst, which is orforglipron’s launch path and payer uptake, or the central risk of pricing and reimbursement pushback on GLP 1 therapies.

    The most relevant recent news for this story is the strong Phase 3 TRANSCEND T2D 1 data for retatrutide, which reinforces Lilly’s push to extend its cardiometabolic franchise beyond Mounjaro and Zepbound. If retatrutide eventually joins orforglipron and existing GLP 1s, it could deepen Lilly’s cardiometabolic ecosystem and potentially help offset concentration risk in a few obesity and diabetes products, although the commercial and regulatory outcomes are still unknown.

    Yet even with these promising trial results, investors should be aware that growing pricing pressure and payer pushback could still...

    Read the full narrative on Eli Lilly (it's free!)

    Eli Lilly's narrative projects $89.1 billion revenue and $34.2 billion earnings by 2028.

    Uncover how Eli Lilly's forecasts yield a $1211 fair value, a 32% upside to its current price.

    Exploring Other Perspectives

    LLY 1-Year Stock Price Chart
    LLY 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenues above US$120 billion and earnings near US$50 billion by 2029, so this new data could either reinforce their view of Lilly’s obesity franchise strength or highlight how exposed those forecasts are if payer resistance and pricing reform, such as formulary exclusions, prove tougher than expected.

    Explore 28 other fair value estimates on Eli Lilly - why the stock might be worth just $883.99!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Curious About Other Options?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.